Fig. 2From: Prognostic impact of CD4-positive T cell subsets in early breast cancer: a study based on the FinHer trial patient populationInfluence of the median breast cancer CXCL13 content on distant disease-free survival in luminal A-like cancer (a), luminal B-like cancer (b), human epidermal growth factor receptor 2 (HER2)-positive cancer (c), and triple-negative cancer (d) in the FinHER trialBack to article page